Tyrosine Kinase Inhibitor (Envisia Therapeutics)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameTyrosine Kinase Inhibitor (Envisia Therapeutics)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProtein-tyrosine kinases inhibitors
TargetsProtein-tyrosine kinases
Therapy Area/IndicationsMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesEnvisia Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEnvisia Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsMacular Degeneration

Other Information

ATC CodeN/A
Related LinksN/A